Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Holmberg

Showing results (141-150 of 169) with videos related to

Pageof 17
Sort By:
Journal of Cancer Research and Clinical Oncology|January 1, 1995
Influence of zymosan (a non-specific macrophage stimulator) and of indomethacin on liver tumours--an experimental study in ratsS B Holmberg, P L Naredi, G O Lindnér, et al.
Folia Phoniatrica Et Logopaedica : Official Organ of the International Association of Logopedics and Phoniatrics (IALP)|February 11, 2009
Item reduction of the voice handicap index based on the original version and on European translationsT Nawka, I M Verdonck-de Leeuw, M De Bodt, et al.
Acta Oncologica (Stockholm, Sweden)|February 9, 2011
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1Per Edlund, Johan Ahlgren, Karsten Bjerre, et al.
Breast Cancer Research and Treatment|March 3, 2010
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancerRobert J Paridaens, Shari Gelber, Bernard F Cole, et al.
Cancer|December 22, 2005
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trialsLorenzo Gianni, Ilaria Panzini, Sigui Li, et al.
Folia Phoniatrica Et Logopaedica : Official Organ of the International Association of Logopedics and Phoniatrics (IALP)|April 25, 2008
Validation of the voice handicap index by assessing equivalence of European translationsI M Verdonck-de Leeuw, D J Kuik, M De Bodt, et al.
Breast Cancer Research and Treatment|February 9, 2008
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93Beat Thürlimann, Karen N Price, Richard D Gelber, et al.
Breast Cancer Research and Treatment|January 13, 2009
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a centuryOlivia Pagani, Karen N Price, Richard D Gelber, et al.
Ugeskrift for Laeger|July 6, 1992
[Malignant melanoma of the skin in Denmark--epidemiology, diagnosis and treatment]H von der Maase, A Osterlind, K T Drzewiecki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VIIA Wallgren, M Bonetti, R D Gelber, et al.
Pageof 17

Showing results (141-150 of 169) with videos related to

Sort By:
Pageof 17
Journal of Cancer Research and Clinical Oncology|January 1, 1995
Influence of zymosan (a non-specific macrophage stimulator) and of indomethacin on liver tumours--an experimental study in ratsS B Holmberg, P L Naredi, G O Lindnér, et al.
Folia Phoniatrica Et Logopaedica : Official Organ of the International Association of Logopedics and Phoniatrics (IALP)|February 11, 2009
Item reduction of the voice handicap index based on the original version and on European translationsT Nawka, I M Verdonck-de Leeuw, M De Bodt, et al.
Acta Oncologica (Stockholm, Sweden)|February 9, 2011
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1Per Edlund, Johan Ahlgren, Karsten Bjerre, et al.
Breast Cancer Research and Treatment|March 3, 2010
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancerRobert J Paridaens, Shari Gelber, Bernard F Cole, et al.
Cancer|December 22, 2005
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trialsLorenzo Gianni, Ilaria Panzini, Sigui Li, et al.
Folia Phoniatrica Et Logopaedica : Official Organ of the International Association of Logopedics and Phoniatrics (IALP)|April 25, 2008
Validation of the voice handicap index by assessing equivalence of European translationsI M Verdonck-de Leeuw, D J Kuik, M De Bodt, et al.
Breast Cancer Research and Treatment|February 9, 2008
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93Beat Thürlimann, Karen N Price, Richard D Gelber, et al.
Breast Cancer Research and Treatment|January 13, 2009
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a centuryOlivia Pagani, Karen N Price, Richard D Gelber, et al.
Ugeskrift for Laeger|July 6, 1992
[Malignant melanoma of the skin in Denmark--epidemiology, diagnosis and treatment]H von der Maase, A Osterlind, K T Drzewiecki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VIIA Wallgren, M Bonetti, R D Gelber, et al.
Pageof 17